EIB Global and WHO Announce €10 Million Grant to Rebuild Lebanon Central Public Health Laboratory and Support Chronic Disease Care

On March 6, 2025, a critical turning point for Lebanon’s healthcare infrastructure was officially marked at the European Investment Bank (EIB) Group Forum in Luxembourg. Dr. Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization (WHO), and Thomas Östros, Vice-President of the European Investment Bank operating through its specialized arm, EIB Global, gathered to sign a landmark financing agreement. The pact commits a €10 million grant dedicated entirely to reinforcing public health systems across Lebanon, a nation currently grappling with unprecedented socioeconomic pressures, infrastructural decay, and compounded humanitarian crises.

This strategic partnership between two of the world’s leading multilateral institutions is designed to address both immediate humanitarian needs and long-term systemic vulnerabilities. At the core of the initiative are two primary objectives: the complete re-establishment and modernization of Lebanon’s Central Public Health Laboratory—which serves as the backbone of disease surveillance and diagnostic integrity for the entire country—and the urgent prioritization of medication distribution and clinical healthcare support for more than 50,000 vulnerable individuals suffering from severe chronic illnesses, including diabetes, cardiovascular diseases, and various forms of cancer.

The signing of this agreement signifies a renewed commitment from the international community to safeguard public health in the Eastern Mediterranean region. By bridging the gap between emergency humanitarian aid and sustainable developmental recovery, the WHO and EIB Global are laying the groundwork for a more resilient healthcare architecture capable of withstanding future shocks.

The Genesis of the Crisis: Background Context of Lebanon’s Healthcare Collapse

To understand the profound significance of the €10 million grant, it is essential to examine the severe degradation that Lebanon’s health sector has endured over recent years. Once regarded as the medical hub of the Middle East, renowned for its advanced private hospitals and skilled medical professionals, Lebanon has experienced a catastrophic economic collapse since 2019. This financial crisis, compounded by the devastating August 4, 2020, Beirut port explosion, the COVID-19 pandemic, ongoing regional geopolitical instability, and massive internal displacement, has pushed public institutions to the brink of total failure.

The Lebanese pound has lost more than 98% of its value against the US dollar, wiping out the purchasing power of ordinary citizens and crippling the state’s ability to import essential goods. Pharmaceuticals, which were heavily subsidized by the central bank, saw subsidies progressively lifted, leading to astronomical price hikes that rendered life-saving medications unaffordable for a vast majority of the population. Consequently, hundreds of thousands of Lebanese citizens suffering from non-communicable diseases (NCDs) have been forced to ration their medication, skip doses, or abandon treatment altogether.

Furthermore, the physical infrastructure of the nation’s health apparatus suffered immense blows. The Central Public Health Laboratory—the premier institution responsible for verifying food safety, water quality, epidemiological surveillance, and infectious disease outbreak response—was severely damaged and lacked the operational capacity, advanced reagents, and modern equipment required to function effectively. Without a functioning central laboratory, health authorities have operated largely in the dark, struggling to monitor emerging health threats, verify pharmaceutical standards, or mount coordinated responses to public health emergencies.

Chronology of Intervention: Milestones Leading to the March 2025 Agreement

The path to the March 6, 2025 agreement has been shaped by years of incremental emergency interventions and escalating alarm bells raised by international health agencies.

2019–2020: The Dual Shocks

The onset of the financial crisis in late 2019 began restricting access to imported medical supplies. This was violently accelerated by the 2020 Beirut port blast, which destroyed or severely damaged numerous medical facilities and warehouses, including structures integral to the national supply chain, placing an immediate burden on international organizations to step in with emergency medical shipments.

2021–2023: Managing the Brain Drain and Medicine Shortages

During these years, the WHO, alongside the European Union and other bilateral donors, launched continuous stop-gap measures. Thousands of doctors, nurses, and specialists emigrated in search of better working conditions, leaving public hospitals understaffed. International agencies focused heavily on procuring basic primary healthcare kits, insulin, and cancer treatments to prevent mass fatalities among chronic disease patients.

2024: Escalating Regional Instability

The intensification of cross-border conflicts in southern Lebanon displaced over 100,000 people and placed additional strain on an already fractured public health system. Medical facilities faced fuel shortages, rendering backup generators unreliable, while clinics in conflict-affected areas struggled to maintain cold chains for vaccines and sensitive medicines.

March 6, 2025: The EIB Global and WHO Partnership Formalized

Meeting at the EIB Group Forum in Luxembourg, Dr. Tedros Adhanom Ghebreyesus and Thomas Östros finalized the €10 million grant agreement. This move transitions international assistance away from purely reactive emergency responses toward structured, institutional recovery, focusing specifically on laboratory restoration and chronic disease management frameworks.

Data-Driven Insights: The Scale of Need and Allocation Strategy

The allocation of the €10 million grant has been meticulously calculated to maximize impact across the Lebanese population, targeting sectors where state provision has completely stalled.

Data compiled by public health monitors indicates that non-communicable diseases account for more than 80% of all mortality in Lebanon. Cardiovascular diseases alone represent the leading cause of death, followed closely by cancers and diabetes complications. Prior to the economic collapse, Lebanon’s Ministry of Public Health maintained comprehensive procurement pipelines for these medications. As state coffers emptied, these pipelines collapsed, leaving an estimated 500,000 individuals with chronic health conditions without reliable state-backed access to treatment.

The new initiative’s targeting of 50,000 individuals with severe chronic diseases represents a prioritized triage model. By focusing heavily on patients suffering from advanced cardiovascular ailments, insulin-dependent diabetes, and oncology requirements, the program addresses the cohort facing the highest risk of acute morbidity and mortality.

On the infrastructural front, the re-establishment of the Central Public Health Laboratory involves several key data-driven benchmarks:

• Diagnostic Accuracy: Upgrading genomic sequencing and microbiological testing equipment to international standards.
• Supply Chain Integrity: Establishing rigorous quality-control protocols for imported pharmaceuticals and local food/water supplies.
• Epidemiological Surveillance: Creating digital data-sharing pathways between regional clinics, hospitals, and central authorities to detect epidemiological anomalies in real-time.

Official Responses and Stakeholder Perspectives

The partnership has garnered significant praise from international health advocates, regional administrators, and institutional stakeholders who view the agreement as a vital lifeline for a neglected population.

Speaking at the EIB Group Forum in Luxembourg, WHO Director-General Dr. Tedros Adhanom Ghebreyesus emphasized the holistic nature of the intervention. He noted that health is a fundamental human right that cannot be sustained without robust institutional backing. Dr. Tedros highlighted that rebuilding the Central Public Health Laboratory is not merely a construction project, but a restoration of national sovereignty over health security. He commended the European Investment Bank for its steadfast solidarity, stating that vulnerable populations in Lebanon deserve access to uninterrupted care, regardless of political or economic turbulence.

Echoing these sentiments, EIB Global Vice-President Thomas Östros underscored the European Union’s commitment to fostering stability and human development in its neighboring regions. Östros remarked that financial institutions must look beyond traditional economic metrics and invest directly in human capital. He stressed that by securing chronic disease treatments and reinforcing public health infrastructure, EIB Global is helping to prevent a deeper humanitarian catastrophe that could destabilize the entire Eastern Mediterranean basin.

While official statements from Lebanese state authorities and local medical syndicates are pending full operational rollout, domestic healthcare workers have expressed cautious optimism. Representatives from Lebanese nursing and medical associations have long argued that piecemeal donations are insufficient to resolve systemic decay. They have welcomed the targeted focus on the Central Public Health Laboratory, noting that independent verification of drug quality and disease tracking are absolute prerequisites for rebuilding public trust in the national health apparatus.

Broader Impact and Implications for Regional Public Health

The long-term implications of the €10 million EIB Global and WHO initiative extend far beyond the immediate borders of Lebanon, offering a blueprint for resilience-building in fragile states.

Strengthening Regional Health Security

In an interconnected world, the health security of one nation directly impacts regional stability. The breakdown of laboratory surveillance in Lebanon previously created a blind spot in the Middle East’s epidemiological monitoring network. By fully re-establishing the Central Public Health Laboratory, the initiative re-establishes a crucial node in international pathogen tracking, reducing the risk of undetected disease outbreaks spreading across borders.

Mitigating Human Suffering and Economic Productivity

Chronic illnesses are not only a medical crisis but an economic one. When breadwinners in a family are incapacitated by untreated diabetes or cardiovascular events, entire households are pushed into extreme poverty. By ensuring that 50,000 high-risk individuals receive continuous access to life-saving medicines, the program preserves workforce participation, reduces catastrophic out-of-pocket health expenditures for impoverished families, and alleviates the burden on emergency room facilities.

A New Paradigm for Multilateral Cooperation

The collaboration between the WHO—the specialized UN health agency—and EIB Global—the financing arm of the European Union—demonstrates the efficacy of bridging technical health expertise with large-scale financial muscle. Analysts suggest that this cooperative model could serve as a template for future international interventions in post-conflict or economically collapsed zones worldwide, proving that developmental banks and health authorities can successfully synchronize their mandates to achieve sustainable outcomes.

Conclusion

As Lebanon continues to navigate its complex web of economic, political, and social challenges, the €10 million grant provided by EIB Global and administered through the WHO represents a vital beacon of hope. By addressing the dual pillars of institutional diagnostic capacity and direct pharmaceutical support for chronic disease sufferers, the initiative moves beyond temporary crisis management toward structural rehabilitation.

The successful implementation of this agreement over the coming months will be closely watched by international donors, regional governments, and public health advocates. If executed according to its ambitious mandate, it will not only restore dignity and health to tens of thousands of Lebanese citizens living with severe illnesses, but it will also re-anchor Lebanon’s public health system on a foundation of scientific rigor, institutional resilience, and enduring international solidarity.